Page last updated: 2024-10-25

desipramine and Bladder, Overactive

desipramine has been researched along with Bladder, Overactive in 2 studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"Desipramine was administered again 2 weeks after the last mirabegron dose."2.79The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. ( Dickinson, J; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; Tretter, R; van de Wetering, J; van Gelderen, M, 2014)
"Desipramine is a potential useful treatment for patients with OAB."1.40Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy. ( Bagadiya, N; Hillelsohn, JH; Kashan, M; Rais-Bahrami, S; Weiss, GH, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Krauwinkel, W1
Dickinson, J1
Schaddelee, M1
Meijer, J1
Tretter, R1
van de Wetering, J1
Strabach, G1
van Gelderen, M1
Hillelsohn, JH1
Rais-Bahrami, S1
Bagadiya, N1
Kashan, M1
Weiss, GH1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol[NCT01478490]Phase 128 participants (Actual)Interventional2002-09-30Completed
An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects[NCT01478568]Phase 128 participants (Actual)Interventional2008-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for desipramine and Bladder, Overactive

ArticleYear
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S

2014
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S

2014
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S

2014
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1

    Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over S

2014

Other Studies

1 other study available for desipramine and Bladder, Overactive

ArticleYear
Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy.
    Urology journal, 2014, Jan-04, Volume: 10, Issue:4

    Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Desipramine; Drug Resistance; Female; Humans;

2014
chemdatabank.com